Summary
BIOCAD is a bio-pharmaceutical company that develops, manufactures and distributes generic pharmaceuticals products. It develops products in urology, gynecology, dermatology, oncology, hematology, autoimmune diseases and infectious diseases therapeutic areas. The company's products are developed through its own research and development (R&D) center, The Center of Immunology Engineering. BIOCAD also carries out clinical trials through laboratories and equipment including department of biochemistry; department of pre-clinical studies; laboratory of molecular genetics; laboratory of genetics recombinant producers; laboratory of antibodies engineering; laboratory of cell engineering and physiology laboratory of recombinant producents. The company also operates in India, Belarus, Ukraine, South Africa, Argentina and Brazil. BIOCAD is headquartered in Saint-Petesburg, Russia.
BIOCAD - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
BIOCAD, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
BIOCAD, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
BIOCAD, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
BIOCAD, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
BIOCAD, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
BIOCAD, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Pfizer Enters Into Licensing Agreement With Biocad For Hemophilia Drug 10
Acquisition 11
Pharmstandard Completes Acquisition of 20% Stake in Biocad 11
Millhouse Completes Acquisition of 50% Stake in Biocad 12
Biocad Rumored To Sell Itself For Up To US$1 Billion 13
Gazprombank Acquires Majority Stake In Biocad, Biotech Company 14
BIOCAD - Key Competitors 15
Key Employees 16
Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18
List of Tables
BIOCAD, Pharmaceuticals & Healthcare, Key Facts 1
BIOCAD, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
BIOCAD, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
BIOCAD, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
BIOCAD, Deals By Therapy Area, 2010 to YTD 2016 8
BIOCAD, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Pfizer Enters Into Licensing Agreement With Biocad For Hemophilia Drug 10
Pharmstandard Completes Acquisition of 20% Stake in Biocad 11
Millhouse Completes Acquisition of 50% Stake in Biocad 12
Biocad Rumored To Sell Itself For Up To US$1 Billion 13
Gazprombank Acquires Majority Stake In Biocad, Biotech Company 14
BIOCAD, Key Competitors 15
BIOCAD, Key Employees 16
BIOCAD, Other Locations 17
BIOCAD, Subsidiaries 17
List of Figures
BIOCAD, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
BIOCAD, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
BIOCAD, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
BIOCAD, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
BIOCAD, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
BIOCAD, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
BIOCAD, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
BIOCAD, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8